Abstract library

34 results for "Singh".
#97 The role of Ki-67 in the prognosis and management of neuroendocrine (NET) patients in a multdisciplinary cancer center
Introduction: The role of Ki-67 in NETs has become increasingly important, especially in light of the current trend in oncology to incorporate pathological molecular characteristics in determining treatment. In North America, Ki-67 is used inconsistently, as there exists some debate in the literature about its predictive value.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Simron Singh
Authors: Singh S, Rowsel C, Ingber N, Yang S, ...
#128 Multidisciplinary reference centers: the need for combined expertise in the diagnosis and treatment of neuroendocrine tumors
Introduction: Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies with increasing incidence (Yao et al. J Clin Oncol 2008;26:3063–72). Multidisciplinary reference centers (MRCs) can potentially offer better clinical outcomes by integrating and coordinating expert care from many specialties, reducing delays in treatments and referrals, and allowing for accrual to clinical trials. MRCs have achieved improved outcomes in ovarian, breast and lung cancers (Pollock. Ann Surg 2008;248:510–6; Gabel et al. Cancer 1997;79:2380–4; Forrest et al. Br J Cancer 2005;93:977–8). Despite this, MRCs focusing on NETs are uncommon.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors: Singh S, Law C, ...
#158 Progression-free survival (PFS) as a primary endpoint for clinical studies in advanced neuroendocrine tumors (NETs)
Introduction: Successfully testing new antitumor agents requires primary study endpoints that are clinically important, and also provide sufficient statistical power within a timeframe and population size that is feasible for the tumor type. Using overall survival (OS) as the primary endpoint in NET studies is challenging because of the low incidence (5.25/100,000 annually), disease heterogeneity, extended survival time (Yao 2008), and confounding effects of multiple therapies. These inherent aspects of NETs make OS an extremely difficult and challenging endpoint to evaluate clinical efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Simron Singh
Authors: Singh S, Law C, ...
#312 Evidence for the role of miR196a in regulating small intestinal neuroendocrine tumor proliferation and metastasis via HOX/AKT pathway activation
Introduction: MicroRNAs (miRNAs) regulate cell proliferation, differentiation, and apoptosis functioning as tumor suppressor genes but their role in NET proliferation and metastasis has not been fully evaluated.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
Authors: Kidd M, Lawrence B, Alaimo D, Svejda B, ...
#496 Progression-Free Survival by Prior Somatostatin Analog Use and Primary Tumor Site and Updated Safety Results in Patients with Advanced Neuroendocrine Tumors and a History of Carcinoid Syndrome: A RADIANT-2 Analysis
Introduction: In RADIANT-2, patients (pts) with advanced neuroendocrine tumors (NET) on Everolimus (E, 10 mg/d) + octreotide LAR (O, 30 mg q28d) had clinically meaningful improvement in progression-free survival (PFS) v. placebo (P)+O (16.4 mo v. 11.3 mo, respectively).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Marianne E Pavel
#535 Epidemology of Neuroendocrine Tumors in Ontario: A 15-year Population-Based Study
Introduction: A recent study of the SEER database in the United States showed a 5-fold increase in neuroendocrine tumors (NETs) over the last 30 years. Conflicting reports of incidence trends have been reported worldwide.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Simron Singh
Authors: Singh S, Cukier M, Saskin R, Liu N, ...
#537 Survival of Patients with Neuroendocrine Cancers in Ontario Over the Last 15 Years
Introduction: There has been an increased incidence of neuroendocrine tumors (NETs) in Ontario, Canada, over the last 15 years but little is known about trends in survival.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Simron Singh
Authors: Singh S, Cukier M, Liu N, Saskin R, ...
Keywords: survival
#539 Patterns of Care of Neuroendocrine Cancer in Ontario: Health Services Delivery
Introduction: Delayed diagnosis and treatment of NETs may result in increased health care utilization, medical costs and patient distress. Patients may be treated by different specialists and modalities.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Simron Singh
Authors: Singh S, Cukier M, Liu N, Saskin R, ...
#1073 The Clinical Oncology Society of Australia (COSA) SIGNETURe Neuroendocrine Tumor (NET) Registry of Australia: First Report of Patient Characteristics and Patterns of Care
Introduction: NETs remain a relatively rare malignancy. Clinical trials are often hindered by the limited number of patients available and thus registries provide important information about patterns of care and patient outcomes.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: A/Prof Timothy Price
Keywords: Registry
#1167 Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases
Introduction: Cowden Syndrome is a multiorgan disorder with germline mutations in the tumor suppressor gene PTEN leading to dysfunctional cell growth and risk of neoplasms in e.g. breast and thyroid, but no association with NET has been described.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Lene Ringholm
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.